Divisas / MRSN
MRSN: Mersana Therapeutics Inc
7.32
USD
0.34
(4.44%)
El tipo de cambio de MRSN de hoy ha cambiado un -4.44%. En este caso, el precio mínimo en el mercado ha alcanzado 7.32, mientras que el máximo ha alcanzado 7.85.
Siga la dinámica de la pareja de divisas Mersana Therapeutics Inc. El gráfico histórico le mostrará cómo ha cambiado el precio de %AssetName% en el pasado. Alternando entre diferentes marcos temporales, podrá monitorear las tendencias y la dinámica del tipo de cambio por minutos, horas, días, semanas y meses. Use esta información para predecir los cambios en el mercado y tomar decisiones comerciales fundamentadas.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
MRSN News
- Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
- Truist Securities slashes Mersana stock price target to $36 from $250
- Guggenheim lowers Mersana stock price target to $30 from $125
- Mersana stock price target raised to $17 from $6 at BTIG
- Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
- Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
- Mersana Therapeutics earnings missed by $4.71, revenue fell short of estimates
- Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
- Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates
- Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates
- Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested - TipRanks.com
- Mersana Therapeutics stock tumbles on 1-for-25 reverse split plan
- Mersana Therapeutics to implement 1-for-25 reverse stock split Friday
- Mersana Therapeutics to implement 1-for-25 reverse stock split
- Mersana reports promising Phase 1 ADC trial results
- Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Truist raises Mersana stock target to $10, maintains Buy rating
- CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
- Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
- Mersana Therapeutics earnings matched, revenue fell short of estimates
- Walmart, Deere, Applied Materials set to report earnings Thursday
Rango diario
7.32
7.85
Rango anual
0.26
8.19
- Cierres anteriores
- 7.66
- Open
- 7.78
- Bid
- 7.32
- Ask
- 7.62
- Low
- 7.32
- High
- 7.85
- Volumen
- 86
- Cambio diario
- -4.44%
- Cambio mensual
- 9.91%
- Cambio a 6 meses
- 1281.13%
- Cambio anual
- 372.26%
30 agosto, sábado